Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Alexion Pharmaceuticals    ALXN

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/20/2017 06/21/2017 06/22/2017 06/23/2017 06/26/2017 Date
119.05(c) 123.58(c) 126.23(c) 126.07(c) 125.09(c) Last
3 592 187 2 929 880 2 863 142 4 530 700 2 916 550 Volume
+2.49% +3.81% +2.14% -0.13% -0.78% Change
More quotes
Financials ($)
Sales 2017 3 473 M
EBIT 2017 1 449 M
Net income 2017 727 M
Debt 2017 1 256 M
Yield 2017 -
Sales 2018 4 019 M
EBIT 2018 1 804 M
Net income 2018 1 063 M
Debt 2018 498 M
Yield 2018 -
P/E ratio 2017 38,87
P/E ratio 2018 26,83
EV / Sales2017 8,51x
EV / Sales2018 7,17x
Capitalization 28 310 M
More Financials
Company
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products.Its products include soliris, strensiq and kanuma.The company was founded... 
Sector
Pharmaceuticals
Calendar
07/27Earnings Release
More about the company
Surperformance© ratings of Alexion Pharmaceuticals
Trading Rating : Investor Rating :
More Ratings
Latest news on ALEXION PHARMACEUTICALS
06/23 ALEXION PHARMACEUTICALS : Receives Positive CHMP Opinion for Soliris® (Eculizuma..
06/14 NASDAQ 100 MOVERS : Biib, alxn
06/14 ALEXION PHARMACEUTICALS : Pharma Appoints Biogen Executive Paul Clancy As CFO
06/14 ALEXION PHARMACEUTICALS : names ex-Biogen exec Paul J. Clancy new CFO
06/13 ALEXION PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financi..
06/13 ALEXION PHARMACEUTICALS : Names Paul Clancy Chief Financial Officer
06/08 ALEXION PHARMACEUTICALS : Technical Snapshots for These Biotech Stocks -- Gilead..
06/02DJAlexion stock rises 1.4% after naming new executives -- MarketWatch
06/01 ALEXION PHARMACEUTICALS : Announces Additions to Executive Leadership Team
05/30DJAKARI THERAPEUTICS : CEO Resigns
More news
Sector news : Biopharmaceuticals
09:28a CROWN RESORTS : China jails Crown Resorts staff over gambling crimes
06/23DJSAMSUNG ELECTRONICS : Makes Play for Drug Market With Version of Humira -- Updat..
06/23DJSAMSUNG ELECTRONICS : Makes Big Play in Drug Market With Cheaper Version of Bloc..
06/23DJOne of the Last Untapped Blockbuster Diseases? Drug Companies Race to Find a ..
06/23 China's ICBC says checks of loans to big acquirers are routine
More sector news : Biopharmaceuticals
Latest Tweets
08:32aAlexion Pharmaceuticals, Inc. $ALXN Stock Rating Reaffirmed by Leerink Swann .. 
06/25$ALXN what about this one?
2
06/25Contrasting Alexion Pharmaceuticals $ALXN & Cesca Therapeutics $KOOL  
06/24Alexion Pharmaceuticals $ALXN Given Media Impact Score of 0.15  
06/23S&P sees mild weekly gain, Nasdaq outperforms as biotech shines $REGN $CE..
9
More tweets
Qtime:124
News from SeekingAlpha
06/23 Buy Hasbro At $110 - Cramer's Lightning Round (6/22/17)
06/20 Biotech Is Well-Positioned To Outperform
06/20 DAILY INSIDER RATINGS ROUND UP 6/19/ : Coty, dltr, glpi, bomn
06/19 DAILY INSIDER RATINGS ROUND UP 6/16/ : Rev, club, arex, opk
06/16 SNIPPET ROUNDUP : Novartis Enters Advair Generic Race, Biogen Dealt CFO Blow
Advertisement
Chart ALEXION PHARMACEUTICALS
Duration : Period :
Alexion Pharmaceuticals Technical Analysis Chart | ALXN | US0153511094 | 4-Traders
Full-screen chart
Technical analysis trends ALEXION PHARMACEU...
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Average target price 155 $
Spread / Average Target 23%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Ludwig N. Hantson Chief Executive Officer & Director
David Richard Brennan Chairman
Julie O'Neill Executive Vice President-Global Operations
David John Anderson Chief Financial Officer & Executive Vice President
Martin MacKay Executive VP, Global Head-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
ALEXION PHARMACEUTICAL..3.04%28 310
BIOGEN7.26%59 460
CSL LIMITED42.74%49 053
GRIFOLS SA39.01%18 339
BIOMARIN PHARMACEUTICA..14.68%16 577
CHONGQING ZHIFEI BIOLO..--.--%4 287
More Results